Literature DB >> 830221

Localization of radiolabeled cardiac myosin-specific antibody in myocardial infarcts. Comparison with technetium-99m stannous pyrophosphate.

G A Beller, B A Khaw, E Haber, T W Smith.   

Abstract

The myocardial uptake of radioiodinated (Fab')2 fragments of antimyosin antibody [125I-(Fab')2] was compared with simultaneously administered 99mTc-pyrophosphate (Tc-PYP) in dogs undergoing coronary occlusion for 24 (N=6) or 72 hours (N=5). Relative concentrations of both agents in normal and infarcted myocardium were related to regional blood flow as determined by distribution of 55Sr-labeled microspheres in the same animals. There was an inverse exponential relationship between 125I-(Fab')2 localization and regional blood flow in 24 hr (r=-0.64) and 72 hr (r=-0.80) occluded animals. The greatest uptake of 125I-(Fab')2 was observed in subendocardial layers of the center of the infarct where regional flow was most severely impaired (1-10% of normal flow). Maximal localization of Tc-PYP was observed in subepicardial layers in samples from the periphery of the infarct where flow was only moderately reduced (31-50% of normal). Differences in distribution of these two agents in ischemic myocardium are probably related to differences in kinetics of exit from the blood pool.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 830221     DOI: 10.1161/01.cir.55.1.74

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  16 in total

Review 1.  Antibodies for molecular imaging in the cardiovascular system.

Authors:  Ban-An Khaw
Journal:  J Nucl Cardiol       Date:  2005 Sep-Oct       Impact factor: 5.952

Review 2.  Choosing a nuclear medicine study for cardiovascular applications.

Authors:  W H Moore
Journal:  Tex Heart Inst J       Date:  1996

3.  Assessment of acute thrombolysis with newly developed myocardial single-photon emission computed tomographic techniques.

Authors:  T Nishimura
Journal:  J Nucl Cardiol       Date:  1995 Mar-Apr       Impact factor: 5.952

4.  Technetium 99m glucarate: what will be its clinical role?

Authors:  M C Gerson; A J McGoron
Journal:  J Nucl Cardiol       Date:  1997 Jul-Aug       Impact factor: 5.952

5.  Noninvasive radionuclide procedures for diagnosis and management of myocardial ischemia.

Authors:  R H Jones; S K Rerych; G E Newman; P M Scholz; W R Howe; H N Oldham; J K Goodrich; D C Sabiston
Journal:  World J Surg       Date:  1978-11       Impact factor: 3.352

Review 6.  Non-invasive assessment of the effects of drugs on acute myocardial infarct size in man.

Authors:  D Maclean
Journal:  Br J Clin Pharmacol       Date:  1979-06       Impact factor: 4.335

Review 7.  Infarct sizing by scintigraphic techniques and nuclear magnetic resonance imaging.

Authors:  E E van der Wall; M G Niemeyer; A de Roos; A V Bruschke; E K Pauwels
Journal:  Eur J Nucl Med       Date:  1990

8.  Technetium-99m antimyosin antibody (3-48) myocardial imaging: human biodistribution, safety and clinical results in detection of acute myocardial infarction.

Authors:  R Taillefer; L Boucher; R Lambert; J Grégoire; D C Phaneuf; H Sikorsa
Journal:  Eur J Nucl Med       Date:  1995-05

9.  Advantages of technetium pyrophosphate scintigraphy over plasma enzyme analysis in estimation of anterior myocardial infarct size.

Authors:  S Saltissi; P S Robinson; M M Webb-Peploe; D J Coltart; D N Croft
Journal:  Br Heart J       Date:  1981-02

10.  Early membrane damage during coronary reperfusion in dogs. Detection by radiolabeled anticardiac myosin (Fab')2.

Authors:  L H Frame; J A Lopez; B A Khaw; J T Fallon; E Haber; W J Powell
Journal:  J Clin Invest       Date:  1983-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.